Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update
May 08, 2023 08:30 ET
|
Prelude Therapeutics, Inc.
Eight abstracts presented at AACR 2023 demonstrate progress of the pipeline Cash runway unchanged, supporting operations into the fourth quarter of 2024 WILMINGTON, Del., May 08, 2023 (GLOBE...
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May
April 27, 2023 08:30 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., April 27, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will...
ITM Enters Cooperation Agreement with Paul Scherrer Institute (PSI) for Co-Development and Upscaled Manufacturing of Terbium-161 for Theranostic Application in Cancer
April 27, 2023 05:00 ET
|
ITM Isotope Technologies Munich SE
Enhancement of ITM’s development and manufacturing activities strengthens ITM’s position as a pioneer and leader in Targeted Radionuclide Therapy (TRT) Garching / Munich, April 27, 2023 – ITM...
ITM Appoints Roger Estafanos as U.S. General Manager and Expands Presence with Opening of U.S. Headquarters in Princeton, New Jersey
April 17, 2023 08:03 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich and Princeton, NJ, April 17, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical theranostics company, today announced that the company has opened its U.S....
Precision Oncology Market Predicted to Garner US$ 202.5 Billion by 2032, At CAGR 9.8%
April 11, 2023 10:16 ET
|
Market.Us
New York, April 11, 2023 (GLOBE NEWSWIRE) -- According to Market.us, The Precision Oncology Market was worth US$ 81.37 billion in 2022 and is expected to reach US$ 202.5 billion by 2032 with a CAGR...
Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
April 11, 2023 08:30 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., April 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced details relating to eight...
ITM, Helmholtz Munich and University Hospital Münster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma
March 13, 2023 06:13 ET
|
ITM Isotope Technologies Munich SE
Garching/Munich, Munich and Münster, Germany, March 13, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, Helmholtz Munich and the Departments of...
Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
February 09, 2023 09:05 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will...
Global Genomic Cancer Panel and Profiling Markets, 2023-2027 - Next Generation Sequencing Fuels a Revolution
February 09, 2023 04:48 ET
|
Research and Markets
Dublin, Feb. 09, 2023 (GLOBE NEWSWIRE) -- The "Genomic Cancer Panel and Profiling Markets by Cancer, by Application, by Tissue and by Gene Type with Screening Potential Market Size, Customized...
NGS-Based RNA-Sequencing Global Market Report 2022: Featuring Illumina, Thermo Fischer Scientific, Oxford Nanopore, Agilent Technologies & BGI
January 03, 2023 07:18 ET
|
Research and Markets
Dublin, Jan. 03, 2023 (GLOBE NEWSWIRE) -- The "NGS-Based RNA-Sequencing Global Market Report 2022: Ukraine-Russia War Impact" report has been added to ResearchAndMarkets.com's offering.The global...